Here's your US drug review and approval news for the week in brief: Sandoz Inc. finally can take its turn to celebrate, as the Novartis AG unit scored a long-awaited approval for its biosimilar of Amgen Inc.'s Neulasta (pegfilgrastim).
Keeping Track: Biosimilars, Novel Approvals, And Ebola
The latest drug development news and highlights from our US FDA Performance Tracker include a Neulasta biosimilar approval for Sandoz, novel approvals for Celgene's Reblozyl and Giskit B.V.'s ExEm Foam, and a submission for Regeneron's Ebola candidate.
